Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H24O2 |
Molecular Weight | 272.382 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(O)C=C4
InChI
InChIKey=VOXZDWNPVJITMN-SFFUCWETSA-N
InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17-,18+/m1/s1
Molecular Formula | C18H24O2 |
Molecular Weight | 272.382 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Alfatradiol (17a-estradiol, Ell-Cranell® alpha) is a stereoisomer of the female hormone 17b-estradiol. It inhibits the conversion of testosterone to the metabolite dihydrotestosterone (DHT) by suppressing 5a-reductase activity. In addition, by inhibiting 17b-dehydrogenase, it impedes the conversion process of androstenedione to testosterone, resulting in a reduction in the syntheses of testosterone and DHT. It also accelerates the conversion of testosterone to estradiol by stimulating aromatase, decreasing the level of testosterone and leading to a reduction in DHT. In addition, alfatradiol (17a-estradiol) has been reported to stimulate the generation of hair follicular matrix cells.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9048584 |
0.2 nM [Ki] | ||
Target ID: CHEMBL3021 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9048584 |
1.2 nM [Ki] | ||
Target ID: CHEMBL1978 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Ell-Cranell® alpha Approved UseAndrogenetic alopecia in women. |
PubMed
Title | Date | PubMed |
---|---|---|
Combined effects of estrogen and progesterone on the anterior cruciate ligament. | 2001 Feb |
|
Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. | 2001 Jan |
|
Differential neuroprotective effects of equine estrogens against oxidized low density lipoprotein-induced neuronal cell death. | 2001 Jul-Aug |
|
Binding of estrogen and progesterone-BSA conjugates to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the effects of the free steroids on GAPDH enzyme activity: physiological implications. | 2001 Jun |
|
Brain region-specific up-regulation of mouse apolipoprotein E by pharmacological estrogen treatments. | 2001 Nov |
|
Modulation by estrogens and xenoestrogens of recombinant human neuronal nicotinic receptors. | 2001 Nov 2 |
|
Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. | 2001 Nov-Dec |
|
Calcineurin as a potential contributor in estradiol regulation of hippocampal synaptic function. | 2002 |
|
Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. | 2002 Jul |
|
Topical estrogens: their effects on connective tissue synthesis in hairless mouse skin. | 2002 Jul |
|
Estradiol protects dopaminergic neurons in a MPP+Parkinson's disease model. | 2002 Jun |
|
17beta-Estradiol reduces excitatory postsynaptic potential (EPSP) amplitude in rat basolateral amygdala neurons. | 2002 Oct 11 |
|
Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. | 2003 Apr |
|
Estradiol regulates the slow Ca2+-activated K+ current in hippocampal pyramidal neurons. | 2003 Jul 16 |
|
Stationary phase with specific surface properties for the separation of estradiol diastereoisomers. | 2003 Jul 25 |
|
[Anti-arrhythmia activity of estradiol valerate and estradiol nitrate]. | 2003 May-Jun |
|
Characterization of an organic anion transport system in a placental cell line. | 2003 Nov |
|
17Beta-estradiol as a receptor-mediated cardioprotective agent. | 2003 Oct |
|
Alpha and beta estradiol protect neuronal but not native PC12 cells from paraquat-induced oxidative stress. | 2004 |
|
The unusual binding properties of the third distinct teleost estrogen receptor subtype ERbetaa are accompanied by highly conserved amino acid changes in the ligand binding domain. | 2004 Jun |
|
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? | 2004 May 4 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22879713
Ell-Cranell® alpha was applied once a day at 3 ml/application using a pre-dosed applicator, and the head was massaged for approximately one minute to facilitate the absorption of the drug.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16042770
17a- and 17b-estradiol caused a concentration-dependent inhibition of spontaneous rat uterine contractility, with an IC50 value of 89.39 and 8.42 uM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:51:16 GMT 2023
by
admin
on
Sat Dec 16 15:51:16 GMT 2023
|
Record UNII |
3VQ38D63M7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1740
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL286452
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
100000092026
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
C81622
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
1926478
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
3VQ38D63M7
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
8057
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
C519808
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
68570
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
DTXSID8022377
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
17160
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
3VQ38D63M7
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
SUB12672MIG
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
ALFATRADIOL
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
57-91-0
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | |||
|
m5029
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
200-354-8
Created by
admin on Sat Dec 16 15:51:16 GMT 2023 , Edited by admin on Sat Dec 16 15:51:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->STIMULATOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|